This book provides a concise overview over the pathology of retinal angiogenic diseases and explains why anti-angiogenic therapy is effective in so many patients. The reader is guided through the various clinical indications for anti-angiogenic therapy and made aware of its merits as well as current challenges and limitations. It is explained how, since its introduction for the treatment of exudative age-related macular degeneration in 2006, anti-angiogenic therapy has revolutionized the way in which we treat a range of ocular diseases. All of the authors are established experts in their respective fields who share their extensive knowledge and clinical experience with the reader. This book is both a valuable introduction to anti-angiogenic therapy in ophthalmology and a day-to-day companion for all ophthalmologists seeing patients with some of the most prevalent retinal diseases.

Autorentext

Andreas Stahl, MD, FEBO, graduated in Medicine from the University of Freiburg, Germany, in 2005. He spent the years 2008-2010 as a Research Fellow in the Department of Ophthalmology, Harvard Medical School, Boston, thanks to a DFG fellowship grant. Since 2011, Dr. Stahl has been Head of the Angiogenesis Research Group at the University Eye Hospital Freiburg, investigating the underlying mechanisms of angioproliferative retinal diseases. Clinically, Dr. Stahl works as a retinal surgeon attending to patients with a broad variety of retinal disorders ranging from retinopathy of prematurity to ischemic retinopathies and age-related maculopathy. Dr. Stahl has been the recipient of numerous awards, including the Innovative Research Award from the German Ophthalmic Society. He is a reviewer for many journals and author of more than 40 articles in peer-reviewed journals as well as several book chapters.

Inhalt
Retinal Vascular Development.- Retinopathy of Prematurity.- Anti-Vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors.- AREDS Supplementation and the Progression Towards Neovascular Exudative AMD.- VEGF-Inhibition in Macular Telangiectasia Type 2.- Diabetic Retinopathy.- Retinal Vein Occlusion.- Pharmacokinetics of Intravitreally Applied VEGF Inhibitors.- Neovascular Glaucoma.- Corneal Neovascular Diseases.- AntiAngiogenic Gene Therapy - Basic Science and Challenges for Translation into the Clinic.